These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38436796)

  • 1. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
    Yoon NR; Na YJ; Lee JH; Song I; Lee EK; Park MH
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):113. PubMed ID: 38436796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
    Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
    Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
    Everest L; Shah M; Chan KKW
    JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
    Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
    PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework.
    de Hosson LD; van Veenendaal LM; Schuller Y; Zandee WT; de Herder WW; Tesselaar MET; Klümpen HJ; Walenkamp AME
    Ann Oncol; 2017 Dec; 28(12):3022-3027. PubMed ID: 29045525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.
    Hammerman A; Greenberg-Dotan S; Feldhamer I; Birnbaum Y; Cherny NI
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):119-122. PubMed ID: 28617621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value measurement of emerging therapeutics in renal cell carcinoma: ASCO value framework and ESMO-MCBS.
    Ha H; Kang JH; Kim DY; Bae SJ; Lee HY
    BMC Health Serv Res; 2022 Jul; 22(1):900. PubMed ID: 35821026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
    Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
    J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS.
    Jiang Q; Feng M; Li Y; Lang J; Wei H; Yu T
    Front Pharmacol; 2020; 11():574511. PubMed ID: 33390946
    [No Abstract]   [Full Text] [Related]  

  • 12. Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups.
    Del Paggio JC; Cheng S; Booth CM; Cheung MC; Chan KKW
    JNCI Cancer Spectr; 2018 Jul; 2(3):pky050. PubMed ID: 31360865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
    Luo J; Ou S; Wei H; Qin X; Peng R; Wang S; Jiang Q
    Front Public Health; 2023; 11():1109668. PubMed ID: 36908440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between control group therapy and magnitude of clinical benefit of cancer drugs.
    Molto C; Tibau A; Bujosa A; Tapia JC; Mittal A; Tamimi F; Amir E
    Sci Rep; 2022 Dec; 12(1):21342. PubMed ID: 36494465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
    Janzic U; Knez L; Janzic A; Cufer T
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
    [No Abstract]   [Full Text] [Related]  

  • 16. The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks.
    Lin S; Huang Y; Dong L; Li M; Wang Y; Gu D; Wu W; Nian D; Luo S; Huang X; Xu X; Weng X
    Front Pharmacol; 2023; 14():1114304. PubMed ID: 36909180
    [No Abstract]   [Full Text] [Related]  

  • 17. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
    Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
    Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
    Saluja R; Everest L; Cheng S; Cheung M; Chan KKW
    JAMA Oncol; 2019 Aug; 5(8):1188-1194. PubMed ID: 31095255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the clinical benefit of pembrolizumab as a first-line agent in advanced solid tumors: A comprehensive review.
    Mohamed A; Salman B; Shaikh AJ
    J Oncol Pharm Pract; 2024 May; ():10781552241252100. PubMed ID: 38710475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.